Advanced & breakthrough therapies: from idea to patient

13/06/19

QbD, Antleron, Inovigate, Eye-Tec, Neuroplast and Anicells would like to invite you to their event on Advanced & Breakthrough therapies. By means of different keynotes that afternoon, they intend to highlight the different aspects of the ATMP-lifecycle.

The afternoon will be ended with a panel discussion about “innovating end-to-end to win, from a single therapy and for the region”. The panel will exist of Philippe De Backer, Pascale Engelen (Flanders.bio), Annie Hubert (Alliance for Regenerative Medicine) and David Callaert (Novartis).

Programme

• 12.00h Welcome + lunch
• 13.00h Introduction – Bart Van Acker, CEO QbD
• 13.15h “GMP for ATMP: one year into the new part IV” – Bram Keymolen, co-founder Eye-Tec
• 14.00h “Innovative technologies fueling personalized cell therapy” – Jan Schrooten, CEO Antleron
• 14.45h BREAK
• 15.15h “Challenges in scaling and control strategy from lab to patient” – Nicolas Theys, Chief Operating Officer Novadip
• 16.00h “Lessons learned from the cell therapy trials. Time for a new approach?” – Jean-Paul Deslypere, CEO Aesculape
• 16.45h “Innovative Funding solutions for breakthrough therapies” – Ingrid Maes, Managing Director Inovigate BE
• 17.15h Panel discussion – “Innovating end-to-end to win, from a single therapy and for the region”
  – Philippe De Backer
  – Pascale Engelen, CO Managing Director Flanders.bio
  – Annie Hubert, Senior Director Alliance for Regenerative Medicine
  – David Callaert, Head of Engineering Global BTDM at Novartis
• 18.15h Network Reception

Registration

Participating in this event cost €150,- . For more information and registration please vistit the event page.